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Abstract
Background and Objective: Hispanics with multiple sclerosis (MS) present
younger and more often with optic neuritis (ON) as compared to Whites in the
western United States. Regional differences related to Hispanic genetic admixture
could be responsible. We investigated the association between global genetic
ancestry and ON and age at onset of MS in Hispanics. Methods: Data were
obtained for 1033 self-identified Hispanics with MS from four MS-based registries
from four academic institutions across the United States January 2016–April
2017. Multivariate regression models, utilizing genetic ancestry estimates for
Native American (NA), African, and European ancestry, were used to assess the
relationship between genetic ancestry and ON presentation and age of MS onset,
defined as age at first symptom. Results: Genetic ancestry and ON proportions
varied by region where NA ancestry and ON proportions were highest among
Hispanics in the southwestern United States (40% vs. 19% overall for NA and
38% vs. 25% overall for ON). A strong inverse correlation was observed between
NA and European ancestry (r = 0.83). ON presentation was associated with
younger age of onset (OR: 0.98; 95% CI: 0.96–0.99; P = 7.80 9 1003) and
increased NA ancestry (OR: 2.35 for the highest versus the lowest quartile of NA
ancestry; 95% CI: 1.35–4.10; P = 2.60 9 1003). Younger age of onset was found
to be associated with a higher proportion NA (Beta: 5.58; P = 3.49 9 1002)
and African ancestry (Beta: 10.07; P = 1.39 9 1003). Interpretation: Ethnic
differences associated with genetic admixture could influence clinical presentation
in Hispanics with MS; underscoring the importance of considering genetic sub-
structure in future clinical, genetic, and epigenetic studies in Hispanics.
Introduction
Multiple sclerosis (MS) is an immune-mediated disease
where geography, ethnicity, and race play a role in disease
susceptibility.1 The incidence rate of MS in Hispanic Amer-
icans has been reported to be 2.9–8.2/100,000, less than
Whites but higher than Asians and Native Americans
(NA).2,3 The clinical presentation of MS is also said to vary
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between Hispanics and Whites. Studies from southern Cali-
fornia have reported that Hispanics develop MS at an ear-
lier age compared to Whites, in particular Hispanics born
and raised in the United States.3,4 Optic neuritis (ON) is a
common initial clinical presentation of MS with a reported
prevalence of 14–20% in predominantly Whites;5–7 how-
ever, in Hispanics, primarily of Mexican background, it has
been reported to range between 32 and 54%.4,8,9 This find-
ing mirrors Asian clinical reports of frequent optic neuritis
as presenting symptom (42%), which is much greater when
compared to studies conducted in White cohorts. Nonethe-
less, recent reports conducted in southeastern United States
do not report ON as the most common presenting symp-
tom which could be due to differences in Hispanic origin.10
Since both ancestry and MS have a known genetic compo-
nent, we hypothesize that the underlying nature of these
clinical observations may be explained by genetic ancestral
differences between Hispanics; where the similarities to
Asian reports may be explained by the genetic NA compo-
nent.
Few studies have examined the relationship between glo-
bal genetic ancestry (or average ancestry across the genome)
and clinical characteristics of MS in admixed popula-
tions.11–13 Nevertheless, the examination of genetic ancestry
in asthma and other autoimmune diseases has explained
some of the genetic underpinnings behind clinical differ-
ences in ethnic groups.14–16 Recently, variations in genetic
ancestry were also shown to explain clinical patterns of
glaucoma and diabetic retinopathy among Hispanics.17,18
Given these successes, assessing genetic ancestry in Hispan-
ics with MS could aid in understanding clinical similarities/
differences between Hispanics and developing future con-
cept models for the genetic origins of MS presentation.
Utilizing the collection of Hispanic Americans within
the Alliance for Research in Hispanic MS (ARHMS;
www.arhms.org) consortium; our aim was to estimate
global genetic ancestry and determine whether ancestry
was an independent factor influencing age of onset and
the presentation of ON as a first symptom in MS.
Methods
The Institutional Review Board at each institution
approved this study and all patients provided informed
consent prior to participation according to the principles
outlined in the Declaration of Helsinki.
Study population
Participants were recruited from four MS tertiary care insti-
tutions that currently participate in ARHMS: University of
Southern California (USC), University of Miami (UM),
University of California San Francisco (UCSF) and San Juan
MS Center in Puerto Rico. ARHMS was created in 2016 with
a broad goal to improve our understanding of MS in the U.S.
Hispanic population using existing epidemiological and
biospecimen registries to investigate the genetic contributions
to disease.10,19 Inclusion criteria includes: (1) a diagnosis of
MS, (2) self-report as Hispanic, (3) ability to complete a
questionnaire using semistructured interview, and (4) con-
sent to share medical records and a blood sample. Self-identi-
fied Hispanics were included using the NIH minority
inclusion criteria; defined as a person who self-identifies as
Hispanic or Latino of Cuban, Mexican, Puerto Rico, South-
ern or Central Americans, or other Spanish culture or origin,
regardless of race.20 Questionnaire and medical records’ data
are captured in CAFE (Common Application Framework
Extensible; cafe.usc.edu) or RedCap (Research Electronic
Data Capture; projectredcap.org).21 This combined cohort
represents one of the largest well-characterized groups of U.S.
Hispanics with MS.10,19.
Clinical characteristics
Clinical characteristics abstracted from the registries were
MS course (relapsing, progressive), family history of MS
(yes/no), age of first symptom, age of diagnosis, ON (yes/
no) as first symptom of MS, and walking status. Disease
duration and lag time were calculated using age at first
symptom and age at diagnosis. A neurological history was
completed and an expanded disability status scale (EDSS)22
was assigned prior to enrollment by an MS specialist (LA,
AC, MB, LT, MO, SD). An EDSS score of ≥6.0 was used to
indicate individuals with ambulatory disability. All partici-
pants met the criteria for MS according to McDonald
Criteria.23
Genotyping
DNA samples were genotyped using a custom Illumina
genotyping array (inclusive of the ExomeChip content)
via the Illumina Infinium platform. This array targeted
>300,000 genetic markers and was designed by the Inter-
national Multiple Sclerosis Genetics Consortium (IMSGC)
to include both ancestry informative markers24 and other
single-nucleotide polymorphisms (SNPs) specific to con-
sortium member interests. Genotyping was conducted at
the John P. Hussman Institute for Human Genomics at
UM, School of Medicine.
Quality control
In total, DNA samples for 1118 MS cases from USC, UM,
UCSF, and Puerto Rico were genotyped. Samples were
excluded based on genotyping call rate ≤98% (n = 5), dis-
crepancy between self-reported and genotyped gender
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(n = 9), excess autosomal heterozygosity >3 standard devi-
ations from the mean (n = 22), identity by descent indica-
tive of sample duplication or relatedness (n = 42), and
population outliers determined using EIGENSTRAT25 as
exceeding 6 standard deviations from the mean for the first
10 principal components (n = 7). Of the remaining 1033,
only 905 MS cases had clinical data available on either age
of onset or presentation of ON.
SNPs were removed due to low genotyping call rate
(≤99.5% for SNPs with minor allele frequency (MAF)
≤5%; ≤99% for SNPs with MAF ≤10% and >5%; and
≤98% for SNPs with MAF > 10%) and deviations from
Hardy–Weinberg equilibrium (P ≤ 1.0 9 1005). Lastly,
SNPs were removed if discordance was observed across
the 34 plate controls which were included in the overall
genotyping experiment.
Population structure and global ancestry
estimates
ADMIXTURE26 was utilized to estimate the global ancestry
proportions of NA, African, and European ancestry within
each individual. Reference population data for 108 NA
from the Human Genome Diversity Project (HGDP)27
were available from the Illumina 650Y, including popula-
tions of Surui and Karitiana from Brazil, and Maya and
Pima from Mexico. A total of 120 Yoruba DNA samples
were obtained from the NHGRI Sample Repository for
Human Genetic Research at the Coriell Institute for Medi-
cal Research, and 232 Spaniard control DNA samples were
obtained from the Centre d’Esclerosi Multiple de Catalunya
(Cemcat) in Barcelona, Spain. Both the Yoruba and Spa-
niard DNA samples were genotyped on the custom Illu-
mina array described above. Using identity by descent
analyses, it was found that only 46 NA were unrelated
(PI_HAT ≤ 0.2), and so these were used as the NA refer-
ence panel. To avoid bias in the reference panel sizes, we
randomly selected 46 unrelated Yorubans and Spaniards
which passed all sample QC to represent the African and
European reference panels, respectively. SNP QC was done
in each reference set separately, and then the overlap
assessed with the variants passing QC in the Hispanic sam-
ple. In total, 14,731 autosomal variants which overlapped
(the custom designed Illumina array and the Illumina 650Y
array) were independent (R2 ≤ 0.1), had MAF > 0.01, were
not in extended regions of linkage disequilibrium, and were
not within 1 MB of any established MS risk loci28 were
used in ADMIXTURE analyses.
Statistical analysis
Demographics and clinical characteristics were compared
between ascertainment sites using ANOVA and Chi-
square tests as appropriate. Tukey’s method or Chi-square
testing was used for pairwise comparison between sites.
Among all participants, we tested for a correlation
between each of the European, NA, and African ancestral
proportions.
To examine the relationship between genetic ancestry
and ON, a multivariable logistic regression model was
used. Ancestry was modeled by inclusion of both the pro-
portion of NA and African ancestry, and covariates
included age of first symptom and sex. Linearity between
the independent variables and the log odds was con-
firmed. To investigate the relationship of younger age of
onset to genetic ancestry, a multivariable linear regression
model was used, adjusting for sex and family history of
MS. Linear model assumptions including linearity
between the independent and dependent variables,
homoscedasticity, and normality were assessed.
To determine if ascertainment site or HLA-DRB1*15:01
(rs3135388),29 HLA-A*02:01 (rs2517840, rs2523822, rs929
5825), HLA-B*44:02 (rs9266773), HLA-B*55:01 (rs38192
84), HLA-DQA1*01:01 (rs13193645), HLA-DQB1*03:02
(rs3998159 and rs3957146), HLA-DRB1*08:01 (rs4713586
and rs7775055), and rs2229092 as well as rs9277565 which
are all MHC variants which have all been associated with
MS Risk in European populations30 would be considered
confounders in a test of association between either ON or
age at first symptom and genetic ancestry, we tested for a
nonzero partial correlation between ON and age at first
symptom with each site (modeled using indicator variables
for each site) and each HLA tag, after controlling for ances-
try. Partial correlations which were statistically different
from zero would suggest that analyses be stratified by the
confounding variable and subsequently meta-analyzed
using inverse variance meta-analysis. The I2 statistic was
used to determine the degree of heterogeneity across stud-
ies defined according to the stratification variable.
For each model, association of phenotype with genetic
ancestry was assessed using both a joint test of NA and
African ancestry as well as calculation of ancestry specific
parameter estimates. For the analysis of ON, ancestry
specific quartiles were then calculated and included in
our multivariable logistic regression model to further
examine the contribution of ancestry to ON presentation.
All statistical analyses were performed using SAS 9.4 and
R 3.0.2.
Results
Demographics
The cohort consisted of 1033 self-identified Hispanic
cases and passed all QC. They were primarily female
(77%, n = 791) with a mean age of ~44 (Table 1). The
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distribution of genetic ancestry proportions significantly
varied among the Hispanic population by region (Fig. 1).
The contribution of each ancestry had a wide range: NA
0–81% (mean: 19%, SD: 18%), European 2–100% (mean:
72%, SD: 20%), and African 0–97% (mean: 9%, SD:
11%). The NA proportions are significantly higher among
Hispanics ascertained in Southern California (mean 40%
compared to 19% overall, P = 1.49 9 1098 for differ-
ences between sites), while higher African proportions
(mean 15% compared to 9% overall, P = 3.04 9 1009
for differences between sites) predominate in individuals
ascertained in Puerto Rico. A strong inverse correlation
was observed between NA and European ancestry
(r = 0.83) and a moderate inverse correlation between
African and European (r = 0.47) (Table S1).
Clinical characteristics
The mean age of first symptom was 31.9 (SD: 10.9) and
for diagnosis (mean: 35.5, SD: 11.4), with significantly
Figure 1. The distribution of genetic ancestry proportions in Hispanics with MS across sites differs. UM, University of Miami, USC, University of
Southern California, PR, San Juan MS Center in Puerto Rico; UCSF, University of California, San Francisco.
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older age of first symptom seen in cases ascertained in
the southeastern United States compared to west coast
(P = 8.59 9 1008 for differences between sites). Family
history of MS was estimated at 13.4% (of n = 1008), with
some differences seen between sites (P = 1.72 9 1002).
ON was frequently more common in individuals ascer-
tained in southern California compared to the other sites
(mean 38% compared to 24.7% overall, P = 6.04 9
1007 for differences between sites). However, no differ-
ences were seen in type of MS and ambulatory disability
(Table 1).
Ascertainment site was identified as a potential con-
founder in a test of association between genetic ancestry
and both age at first symptom and ON (P < 5.0 9 1002
for partial correlations of each phenotype and site after
controlling for genetic ancestry, data not shown). There-
fore, regression analyses were done within each site, and
parameter estimates were combined across sites using an
inverse variance meta-analysis. HLA was not determined
to be a confounder for the test of association between
genetic ancestry and either age at first symptom or ON
(P > 5.0 9 1002 for partial correlations of each pheno-
type and different HLA tags after controlling for genetic
ancestry, data not shown), and so no further analytical
consideration for HLA was necessary.
Optic neuritis
Genetic ancestry was found to be significantly associated
with ON as the presenting symptom, after adjusting for
sex and age at first symptom (joint test of NA and African
ancestry after controlling for site, P = 3.01 9 1003). This
ancestral association was primarily explained by NA ances-
try (OR = 6.06, 95% CI = 1.94–18.96, P = 1.95 9 1003,
Table 2). To further explain the association between NA
ancestry and ON presentation, the distribution of ON by
quartiles of NA ancestry was examined (Table 2). From
the lowest to highest quartiles of NA ancestry, the fre-
quency of ON as the presenting symptom was statistically
different (16%, 21%, 25%, and 38%, respectively with
P = 3.45 9 1007). To analyze all quartiles simultane-
ously, ascertainment site was included as a covariate in the
regression model, in addition to sex and age at first symp-
tom. We found that those in the highest quartile of NA
ancestry had a ~2.4 increased likelihood of ON
(OR = 2.35, 95% CI = 1.35–4.10, P = 2.6 9 1003) com-
pared to those in the lowest quartile (Table 3).
Age of onset
When we evaluated the association of genetic ancestry
with age at first symptom using multivariate linear regres-
sion we observed a significant association between genetic Ta
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ancestry and age of first symptom (P = 6.37 9 1004 for
the joint test of NA and African ancestry). Both an
increase in African (beta = 10.07, P = 1.39 9 1003)
and NA (beta = 5.58, P = 3.49 9 1002) ancestry con-
tributed to a younger age at first symptom (Table 2,
Fig. S1), although heterogeneity across sites was observed.
The presence of any family history or sex does not appear
to significantly impact the likelihood of presenting with
MS at a younger age of onset. A sensitivity analysis con-
firmed that limiting family history to first-degree relatives
also showed no association with age of onset (P = 0.342).
Discussion
Using 14,731 independent genetic markers, we estimated
global ancestry among the largest collection of self-identi-
fied Hispanics with MS in the United States. We found
significant associations between increasing NA ancestry
and both clinical presentation of ON and earlier age of
disease onset in MS. In addition, we observed that His-
panics with MS are admixed and as expected derive from
the original indigenous natives of America and both
European and African settlers.31 These findings are in line
with previous reports that reflect the expected settlers in
the regions ascertained. The Hispanic population is
diversely distributed, with persons of Mexican origin
mostly living in the southwestern parts of the United
States. Those of South American, Puerto Rico, and Cuban
origins reside primarily along the East Coast of the Uni-
ted States.32,33 Notable differences have been reported in
ancestral admixture: those of Mexican origin tend to have
higher proportions of NA, while the same is true of
Puerto Rico and African ancestry.34,35 These findings
highlight the importance of incorporating population
genetic structure in clinical MS studies.
The most common pathologic basis for optic neuritis is
likely to be inflammatory demyelination of the op-
tic nerve occurring at presentation in ~20% of all MS
cases and typically presenting with a subacute painful
visual loss.36 The few reports comparing Hispanics and
non-Hispanic Whites with MS indicate this to be most
common in Hispanics of Mexican and Central American
background, alluding to their common Asian heritage as
a potential source.3,4,8 An early study from Mexico
reported ON as presenting symptom in 33%, a much
higher proportion when compared to White historical
cohorts.8 The observations that any deviation in the pre-
sentation and clinical progression of MS in Hispanics
from Whites could be influenced by genetic admixture,
until now, were simply speculative.4,8,10,37
While GWAS studies in MS have been successful in pro-
viding us with >200 candidate genes of interest outside of
the MHC in Whites,38 we have little information regarding
candidate genes in other populations nor their candidacy
related to the regional distribution of where MS plaques or
demyelination occur. The possibility exists that genetic
and to some extent environmental factors in MS related to
ethnicity are playing a role in characterizing the process of
axonal loss and neurodegeneration, neuroprotection, and
perhaps neurorestoration as well. Studies of other chronic
diseases, such as Type 2 Diabetes, have observed that His-
panics have a higher prevalence of diabetic retinopathy
compared to Whites.39 In a recent study using genetic
admixture in Hispanics, having a higher proportion of
Native American ancestry was found to be associated with
severe diabetic retinopathy, alluding to the possible genetic
effect on diabetes’ manifestation.18 Studies of systemic
lupus erythematous have also identified an increase in
autoantibody reactivity in non-Whites,40 leading to shifts
in the understanding that genetically determined ancestry
is involved in the biological processes that increase lupus
prevalence and disease severity. Thus, we propose that
future studies should incorporate multiethnic cohorts and
genetic ancestry to better address markers of disease pro-
cess in both ON and MS.
We find that global ancestry estimates partly account
for the observed ON presentation in Hispanics with MS
and could be responsible for the predominant observation
of optic nerve and motor involvement in MS across His-
panics in the United States and Latin America.41,42 How-
ever, sex and age of onset had less of an effect on the risk
of ON as a first symptom of MS. Of note, because not all
patients presenting with ON will go on to develop MS43,
our results suggest more broadly that studies of ON in
non-MS cohorts may benefit from studies of admixed
populations.
Table 3. Likelihood of optic neuritis presentation by quartiles of
native American ancestry.
Variables in model OR (95% CI) P
Native American ancestry
2nd vs. 1st Quartile 1.27 (0.77–2.10) 3.49 9 1001
3rd vs. 1st Quartile 1.29 (0.76–2.19) 3.44 9 1001
4th vs. 1st quartile 2.35 (1.35–4.10) 2.60 9 1003
African ancestry 0.48 (0.10–2.41) 3.74 9 1001
Sex (Female vs. Male) 1.20 (0.82–1.77) 3.46 9 1001
Age at first symptom 0.98 (0.96–0.99) 7.80 9 1003
Site
PR vs. UM 1.98 (1.11–3.53) 2.00 9 1002
USC vs. UM 1.65 (1.00–2.71) 4.88 9 1002
UCSF vs. UM 1.33 (0.79–2.25) 2.83 9 1001
Bold indicates the highest quartile of NA ancestry increases the likeli-
hood of ON presentaiton by more than 2 fold.
PR, San Juan MS Center in Puerto Rico; UM, University of Miami;
USC, University of Southern California; UCSF, University of California,
San Francisco.
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Predominantly White natural history cohorts have sug-
gested a favorable prognosis for presentation with ON as
a first symptom.44,45 However, recent reports have
demonstrated that this may not necessarily indicate a
phenotypic advantage.46,47 Differences in ON recovery
and severity of episodes have been observed in African
Americans when compared to Whites.46,47 Future studies
on the relationship between ON presentation, ancestry,
and severity would be beneficial.
Our finding that higher proportions of NA and African
ancestry increase the chance of presenting with MS at a
younger age is of great interest as well. A recent study that
compared Hispanics and African Americans to Whites
ascertained in the Northeastern United States, with similar
socioeconomic background, indicated that Hispanics have
a younger age of onset compared to Whites and a similar
age of onset to African Americans.37 Previous studies have
also observed an even more pronounced age of onset dif-
ference between U.S. and non-U.S. born Hispanics, sug-
gesting that geographical and environmental changes are
also likely to influence clinical onset.4,48 This could in part
explain the heterogeneity of the observed ancestral effects
across sites. Unfortunately, because factors related to place
of birth and age of migration to the United States are not
currently available for this cohort, we are unable to incor-
porate these factors. Nevertheless, because we were con-
cerned about the potential residual confounding that
geographical variation could pose to our investigation we
included site of ascertainment in our models. In the future,
as we examine disease severity by race and ethnicity, an
investigation of the relationship of genetic ancestry and
sociodemographic factors15 in MS will be important. In
order to pinpoint the genetic regions underlying our
observed effects of increased NA ancestry, future studies
may focus on local ancestry and include an assessment of
the previously reported relationship between HLA-DRB1
positivity and an earlier age of onset.49,50
Limitations and strengths
There are several limitations to our study including the
small, geographically limited, reference NA dataset avail-
able from HGDP, which curtails the degree of precision
in our NA ancestry estimates and our ability to infer cau-
sal relationships. We acknowledge that self-reported eth-
nicity has relevance in health disparity and that
sociocultural and socioeconomic (SES) factors may influ-
ence who seeks care for ON, potentially resulting in over-
or underreporting. Whether SES is a confounder in the
analysis of genetic ancestry and phenotypic presentation
of MS is unknown. Nevertheless, while our study did not
specifically adjust for SES, we did adjust for recruitment
site intentionally to account for any potential residual
confounding. Research supports that lower SES is associ-
ated with poor access to care and non-European ances-
try,15 and that MS risk in Hispanics is associated with
greater European ancestry,12 then it is possible that the
recruitment is biased toward those that have greater
access to care, have higher SES, and greater European
proportions would be expected since ON is a common
presentation in Hispanics.4 Thus, the possibility that our
results are due to SES makes it less likely and any concern
for an overestimation of ON in Hispanics with high
Native American ancestry biasing our results should be
lessen. Nevertheless, our study should follow with more
granular analysis specific to ON outcomes (i.e., severity,
recovery, OCT measures) and SES measurements (insur-
ance status, language barriers, time to diagnosis, medica-
tion compliance, level of education, cultural differences,
etc.). In addition, registry-based participation and the
confirmation of diagnosis with ON via medical record
lessens the potential of overreporting. Yet, there are sev-
eral important strengths which includes the large sample
size, the priori definitions used to assess Hispanic and the
consistency of data collection used across MS centers
which combined are representative of the broad and
diverse Hispanic U.S. population. The potential for gener-
alizability is also a strength that should encourage future
studies of genetic predispositions for modifiable factors
using genetic ancestry. Leveraging genetic ancestry may
prove helpful in uncovering novel disease mechanisms
underlying clinical outcomes in MS; something that has
not previously been successful in even the largest MS
genetic datasets of European ancestry.
Conclusion
The integration of global ancestry estimates in our assess-
ment of ON as first symptom and age of onset with MS
in Hispanics provides a framework for utilizing admixture
to elucidate genetic factors contributing to the observed
clinical variation in MS. The recent formation of the first
U.S.-based Hispanic MS consortium, ARHMS will serve
as a fundamental resource to better understand how clini-
cal, genetic, and environmental factors interplay in MS
risk, disability, and clinical features within the Hispanic
population.
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Figure S1. Age of onset in MS and corresponding quar-
tiles of African and Native American ancestry. Quartile 0:
minimum, Quartile 1: lower quartile, Quartile 2: middle
quartile, Quartile 3: upper quartile.
Table S1. A stronger inverse correlation is observed
between Native American and European ancestry.
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